Douglas Wight

wightMr. Wight is a seasoned drug development professional with over 25 years experience in key strategic drug development roles in academia, and the pharmaceutical and the CRO industries. Mr. Wight began his career in academia, conducting research in pulmonary physiology at McGill University and the Université de Montréal. He then joined the pharmaceutical industry with Sandoz (now Novartis), then moved to Searle (now Pfizer). He later joined the CRO industry with MDS Pharma Services (now Celerion).

During his career, Mr. Wight worked in many different therapeutic areas, including cardiovascular, CNS and metabolic disorders. Most recently at Celerion, Mr. Wight was a Senior Director responsible for the strategic and operational oversight of entire drug development programs from discovery through clinical proof of concept (PoC) for Celerion clients, including therapies for type 2 diabetes, spinal cord injury, hepatocellular carcinoma and acute bacterial infection. Mr. Wight received his Masters degree in Physiology from McGill University in 1985.